Kiromic BioPharma Expands Clinical Trials with Key Partnership
Kiromic BioPharma Expands Deltacel-01 Clinical Trials
Kiromic BioPharma, Inc. (OTCQB: KRBP) is thrilled to announce the activation of the University of Arizona Cancer Center (UACC) as the fifth clinical trial site for its Deltacel-01 Phase 1 trial. This trial is dedicated to evaluating the promising Deltacel™ (KB-GDT-01), focused on patients battling stage 4 metastatic non-small cell lung cancer (NSCLC) after failing standard treatments.
Partnership with the University of Arizona Cancer Center
The UACC is esteemed as one of the 57 NCI-Designated Comprehensive Cancer Centers across the United States. Dr. Ricklie Ann Julian, an Assistant Professor of Medicine at UACC, is set to lead the team as the Principal Investigator for this site.
Optimism at Kiromic BioPharma
Pietro Bersani, CEO of Kiromic BioPharma, expressed enthusiasm about this new venture, stating, "We are delighted to partner with UACC. We believe we are well-positioned to enroll the next cohort of patients, and we are optimistic that we will continue to register encouraging results during the study's expansion phase. The UACC has built a solid reputation as a leading research institution and we are eager to collaborate with their esteemed team."
Following the initiation visit at UACC, the enrollment of patients is anticipated to commence shortly.
Understanding the Deltacel-01 Trial
The ongoing Phase 1 clinical trial, titled "Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Stage 4 Metastatic Non-Small Cell Lung Cancer", involves administering two intravenous infusions of Deltacel™ alongside four courses of targeted low-dose radiation over a span of 10 days. The trial's main aim is to evaluate safety, with secondary goals assessing response rates, progression-free survival, overall survival, and disease control rates.
Deltacel™: A Promising Treatment
Deltacel™ (KB-GDT-01) represents an innovative gamma delta T-cell therapy currently being explored in the Deltacel-01 trial for stage 4 metastatic NSCLC treatment. This allogeneic product consists of donor-derived gamma delta T cells, showcasing Kiromic’s commitment to developing a robust GDT platform. Initially targeting solid tumors, with NSCLC accounting for a significant portion of lung cancer cases, Deltacel™ has shown an encouraging safety and efficacy profile, especially when paired with low-dose radiation.
The Mission of Kiromic BioPharma
Kiromic BioPharma is recognized as a fully integrated, clinical-stage biotherapeutics company leveraging its proprietary DIAMOND® artificial intelligence (AI) engine for target discovery and cell therapy development. This multi-indication allogeneic cell therapy platform aims to exploit the inherent capabilities of Gamma Delta T-cells to combat solid tumors effectively. Located in Houston, Texas, Kiromic stands at the forefront of biotherapeutic advancements.
Conclusion
The recent collaboration with the University of Arizona Cancer Center marks a pivotal moment for Kiromic BioPharma as it strives to push the boundaries of cancer treatment. The Deltacel-01 trial holds promise not only for those suffering from NSCLC but also signifies a substantial step forward in the broader field of immuno-oncology.
Frequently Asked Questions
What is the Deltacel-01 trial?
The Deltacel-01 trial is a Phase 1 clinical study assessing the safety and tolerability of gamma delta T-cell infusions for stage 4 metastatic NSCLC patients.
Where is the Deltacel-01 trial being conducted?
The trial is being conducted at multiple sites, now including the University of Arizona Cancer Center, among others.
What is the primary goal of the Deltacel-01 trial?
The primary goal is to evaluate the safety of Deltacel™ treatment in patients with advanced lung cancer.
What is Deltacel™?
Deltacel™ (KB-GDT-01) is an investigational gamma delta T-cell therapy designed to target solid tumors like NSCLC.
Who is leading the trial at the University of Arizona Cancer Center?
Dr. Ricklie Ann Julian, Assistant Professor of Medicine, is the Principal Investigator at the UACC for the Deltacel-01 trial.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- QNB Group Enhances Financial Position with Successful Loan Refinancing
- Key Insights for Xiao-I Corp. Investors Amid Legal Action
- Investor Alert: Key October Deadline for STMicroelectronics Case
- Elliott Investment Management Engages with Southwest Airlines
- Trump's Momentum Grows in Key Voting Regions as Election Day Nears
- DermRays Expands Horizon with New Amazon Germany Store Launch
- Betterment Transitions Investors from Crypto to ETFs with Ease
- Key Social Security Changes to Expect in 2025 for Retirees
- Tropical Storm Nadine Approaches Belize With Moderate Winds
- Boeing Workers on Brink of Resolving Strike with New Proposal
Recent Articles
- AngioDynamics Launches Groundbreaking RECOVER-AV Trial
- Saul Centers Upholds Dividends Amid Positive Financial Growth
- Essent Group Ltd. Receives Stable Rating from AM Best Agency
- Leadership Changes at Malibu Boats and Future Prospects
- Learn CW Investment Corp Secures $4.8 Million Funding Boost
- Understanding Market Trends and Procter & Gamble's Future
- Exploring Recent Activity and Insights on Lowe's Companies
- Chewy Inc. Expands Stock Strategy with Significant Offering
- Blueprint Medicines: A Bright Future Ahead Amid Market Concerns
- Centessa Pharmaceuticals Receives Positive Morgan Stanley Upgrade
- Early Halloween Shopping Trends Reflect Changing Consumer Habits
- Neumora Therapeutics' Insider Selling Sparks Investor Interest
- Recent Insider Selling Highlights Stronghold Digital Mining's Moves
- Dana-Farber Cancer Institute and Clinical.ly Join Forces
- Key Share Sales Highlight Stronghold Digital Mining's Journey
- Rural Development Partners Secures $65 Million for Community Growth
- Addressing Homelessness: Insights from Chicago's First CHO
- Lennar Corp Reports Significant Growth in Q3 Home Deliveries
- MillerKnoll Faces Challenges with Q1 Results and Guidance
- MACOM Executive's Stock Sales Highlight Company Confidence
- Coastal Financial Corp Insider Activity: A Closer Look
- Middlefield Banc Corp's CEO Invests $6K, Reflecting Confidence
- Stock Market Insights: FedEx, Nike, Chewy Performance Review
- Michael Saylor Shares Optimism as Bitcoin Climbs Beyond $63K
- Evaluating the Recent Fed Rate Cut: Impacts on the Economy
- Innovative Leadership Program Set to Transform Blood Centers
- NIO Inc. Strengthens Team with Former Tesla Managers
- New Consumer Guide Series by National Association of Realtors
- Celebrating the Next Generation: Freedom Award Forum 2024
- Innovative Advances in Internal Combustion Engines Explored
- Battalion Oil Corporation Enhances Merger Deal with Fury Resources
- Zenas BioPharma Expands Offering with Additional Shares Sale
- Biodexa Pharmaceuticals Announces Significant ADR Ratio Update
- KBR's Joint Venture Chosen for Significant LNG Transformation Project
- Coherent Unveils Alpha Release of Advanced Optical Modules
- Cryptocurrency Market Boost: Signals for Future Growth
- Alabama Always, LLC Takes Action to Reform Cannabis Licensing
- PepGen's Board Transition: Dr. Ashton Announces Retirement
- Dime Community Bancshares Expands Team for C&I Lending Growth
- Owens Corning Delivers Solid Dividend for Shareholders
- European Psychedelics Reform Initiative Aims for Major Change
- Territorial Bancorp Confirms Commitment to Hope Bancorp Merger
- Orion S.A. Announces Noteworthy Interim Dividend for Shareholders
- Territorial Bancorp Is Poised for Growth with Hope Merger
- Supernus Pharmaceuticals Engages in Key Neuropsychiatry Event
- Excelerate Energy Partners with Wärtsilä for Eco-Friendly Retrofit
- Supernus Pharmaceuticals Showcases Commitment at Neuropsychiatry Summit
- Chewy, Inc. Launches Offering of Class A Common Stock
- Exploring Recent Trends and Opportunities in the Cannabis Market
- Insights on Corporación América Airports S.A. August Traffic Stats